Effector Therapeutics Inc Cash Flow Quality Index
Effector Therapeutics Inc cash flow quality index. Effector Therapeutics Inc (EFTR) has a Cash Flow Quality Index of -2.12x as of March 2022. Operating cash flow of $-6.50 Million is below net income of $3.07 Million, suggesting accrual-heavy earnings not yet converted to cash. See Effector Therapeutics Inc (EFTR) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Effector Therapeutics Inc (2020–2021)
Cash flow quality index of Effector Therapeutics Inc from 2020 to 2021. Historical Cash Flow Quality Index for Effector Therapeutics Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore EFTR cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Effector Therapeutics Inc Cash Flow Quality Index by Year (2020–2021)
Effector Therapeutics Inc cash flow quality index by year from 2020 to 2021. Year-by-year earnings quality comparison for Effector Therapeutics Inc. For the full cash flow conversion analysis, see cash efficiency ratio of Effector Therapeutics Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | -1.58x | $-24.89 Million | $15.80 Million | ▼ -261.8% |
| 2020 | 0.97x | $13.84 Million | $14.21 Million | — |